These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1120 related items for PubMed ID: 20412793

  • 1. Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.
    Kida T, Fujii A, Sakai O, Iemura M, Atsumi I, Wada T, Sakaki H.
    Exp Eye Res; 2010 Jul; 91(1):85-91. PubMed ID: 20412793
    [Abstract] [Full Text] [Related]

  • 2. Anti-anaphylactic activity of the novel selective histamine H1 receptor antagonist mizolastine in the rodent.
    Levrier J, Duval D, Prouteau M, Voltz C, Berry CN, Lloyd KG, Scatton B.
    Arzneimittelforschung; 1995 May; 45(5):559-68. PubMed ID: 7541995
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
    Abelson MB, Torkildsen GL, Williams JI, Gow JA, Gomes PJ, McNamara TR, Bepotastine Besilate Ophthalmic Solutions Clinical Study Group.
    Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of ketotifen fumarate, olopatadine, and levocabastine on ocular active anaphylaxis in the guinea pig and ocular immediate hypersensitivity in the albino rat.
    Schoch C.
    Ocul Immunol Inflamm; 2005 Feb; 13(1):39-44. PubMed ID: 15804768
    [Abstract] [Full Text] [Related]

  • 7. Role of substance P in experimental allergic conjunctivitis in guinea pigs.
    Yamaji M, Takada M, Fujiwara R, Ohishi H, Izushi K, Sugimoto Y, Kamei C.
    Methods Find Exp Clin Pharmacol; 1997 Nov; 19(9):637-43. PubMed ID: 9500128
    [Abstract] [Full Text] [Related]

  • 8. Suppression by bepotastine besilate of substance P-induced itch-associated responses through the inhibition of the leukotriene B4 action in mice.
    Andoh T, Kuraishi Y.
    Eur J Pharmacol; 2006 Oct 10; 547(1-3):59-64. PubMed ID: 16914135
    [Abstract] [Full Text] [Related]

  • 9. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.
    Williams JI, Kennedy KS, Gow JA, Torkildsen GL, Abelson MB, Gomes PJ, McNamara TR, Bepotastine Besilate Ophthalmic Solutions Study Group.
    J Ocul Pharmacol Ther; 2011 Aug 10; 27(4):385-93. PubMed ID: 21649522
    [Abstract] [Full Text] [Related]

  • 10. Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo.
    Galatowicz G, Ajayi Y, Stern ME, Calder VL.
    Clin Exp Allergy; 2007 Nov 10; 37(11):1648-56. PubMed ID: 17877767
    [Abstract] [Full Text] [Related]

  • 11. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases.
    Sharif NA, Xu SX, Miller ST, Gamache DA, Yanni JM.
    J Pharmacol Exp Ther; 1996 Sep 10; 278(3):1252-61. PubMed ID: 8819509
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Inhibition of human eosinophil chemotaxis in vitro by the anti-allergic agent emedastine difumarate.
    el-Shazly AE, Masuyama K, Samejima Y, Eura M, Ishikawa T.
    Immunopharmacol Immunotoxicol; 1996 Nov 10; 18(4):587-95. PubMed ID: 8933171
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Antiallergic action of betotastine besilate (TAU-284) in animal models: A comparison with ketotifen.
    Ueno M, Inagaki N, Nagai H, Koda A.
    Pharmacology; 1998 Oct 10; 57(4):206-14. PubMed ID: 9730778
    [Abstract] [Full Text] [Related]

  • 16. Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge.
    Torkildsen GL, Williams JI, Gow JA, Gomes PJ, Abelson MB, McNamara TR, Bepotastine Besilate Ophthalmic Solutions Clinical Study Group.
    Ann Allergy Asthma Immunol; 2010 Jul 10; 105(1):57-64. PubMed ID: 20642205
    [Abstract] [Full Text] [Related]

  • 17. Modulation of eotaxin formation and eosinophil migration by selective inhibitors of phosphodiesterase type 4 isoenzyme.
    Silva PM, Alves AC, Serra MF, Pires AL, Silva JP, Barreto EO, Cordeiro RS, Jose PJ, Teixeira MM, Lagente V, Martins MA.
    Br J Pharmacol; 2001 Sep 10; 134(2):283-94. PubMed ID: 11564646
    [Abstract] [Full Text] [Related]

  • 18. A dual antagonist for chemokine CCR3 receptor and histamine H1 receptor.
    Suzuki K, Morokata T, Morihira K, Sato I, Takizawa S, Kaneko M, Takahashi K, Shimizu Y.
    Eur J Pharmacol; 2007 Jun 01; 563(1-3):224-32. PubMed ID: 17336292
    [Abstract] [Full Text] [Related]

  • 19. Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis.
    Macejko TT, Bergmann MT, Williams JI, Gow JA, Gomes PJ, McNamara TR, Abelson MB, Bepotastine Besilate Ophthalmic Solutions Clinical Study Group.
    Am J Ophthalmol; 2010 Jul 01; 150(1):122-127.e5. PubMed ID: 20488431
    [Abstract] [Full Text] [Related]

  • 20. Leukotriene B4 mediates substance P-induced granulocyte infiltration into mouse skin. Comparison with antigen-induced granulocyte infiltration.
    Iwamoto I, Tomoe S, Tomioka H, Yoshida S.
    J Immunol; 1993 Aug 15; 151(4):2116-23. PubMed ID: 7688393
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.